NCI Precision Medicine Study Hones in on Cancer Remission
Researchers say a non-chemotherapy treatment is causing more cancer patients to experience full remission.
A recent National Cancer Institute study shows that a new targeted therapy can help prolong the time cancer patients are in remission. Called the ViPOR regimen, the non-chemotherapy treatment shrinks tumors of those who suffer from B-cell lymphoma.
Dr. Christopher Melani, associate research physician with the Lymphoid Malignancies Branch in the Center for Cancer Research at NCI, highlights the importance of combining five therapies and administering them during a fixed cycle to maximize drug synergy and make tumors disappear.
He also shares details about the second phase of the study that is expected to take place later this year as well as how precision medicine could potentially lead to a cure for all types of cancer.
-
Dr. Christopher Melani Associate Research Physician, Lymphoid Malignancies Branch, Center for Cancer Research NCI
-
The Security and UX Standards That Power Digital Identity Programs
Live from Identity Week, Ryan Galluzzo discusses the latest draft of NIST's Digital Identity Guidelines for the identity-proofing process.
18m listen -
VA Delivers Record-Breaking Care Amid Surging Demand
Agency officials Dr. Shereef Elnahal and Joshua Jacobs said additional funding would sustain increased services to veterans.
4m read -
GSA Cloud Chief Talks FedRAMP 2.0, Automation Hub
Eric Mill shares how a new pilot will inform continuous assessments plus more on software development resources and generative AI.
24m listen -
NSF Funds 5 Centers to Expand Biotechnology Research
The agency sees biotechnology as one of five emerging industries for its applications in health and the environment.
4m read
